Opdivo-话题@MedSci

#Opdivo#

81篇内容 | 2650人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1303074, encodeId=ee5313030e43a, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=百时美施贵宝的PD-1单抗Opdivo未来增长前景堪忧, objectType=article, longId=158911, objectId=f601158911df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f601158911df, replyNumber=0, likeNumber=54, createdTime=2019-01-27, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f601158911df, moduleTitle=百时美施贵宝的PD-1单抗Opdivo未来增长前景堪忧, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f601158911df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303073, encodeId=653213030e3e5, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=FDA延长了对Opdivo/Yervoy联合治疗方案的审查, objectType=article, longId=151495, objectId=41d015149554, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41d015149554, replyNumber=0, likeNumber=57, createdTime=2018-10-23, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41d015149554, moduleTitle=FDA延长了对Opdivo/Yervoy联合治疗方案的审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41d015149554)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303072, encodeId=904f13030e275, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=澳大利亚TGA批准OPDIVO（nivolumab）治疗肝癌, objectType=article, longId=149518, objectId=81ba14951861, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81ba14951861, replyNumber=0, likeNumber=55, createdTime=2018-09-26, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81ba14951861, moduleTitle=澳大利亚TGA批准OPDIVO（nivolumab）治疗肝癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81ba14951861)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303071, encodeId=fc7013030e1a7, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Opdivo vs. Keytruda中国PD-1/L1市场的激烈角逐, objectType=article, longId=147595, objectId=46d414e59525, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46d414e59525, replyNumber=0, likeNumber=65, createdTime=2018-08-30, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46d414e59525, moduleTitle=Opdivo vs. Keytruda中国PD-1/L1市场的激烈角逐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46d414e59525)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303070, encodeId=5ea413030e04f, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=美国食品药品监督管理局批准Opdivo®新适应症成为全球近20年来用于经治小细胞肺癌的新药, objectType=article, longId=147166, objectId=a7ea14e16667, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7ea14e16667, replyNumber=0, likeNumber=66, createdTime=2018-08-23, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7ea14e16667, moduleTitle=美国食品药品监督管理局批准Opdivo®新适应症成为全球近20年来用于经治小细胞肺癌的新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7ea14e16667)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303069, encodeId=0e4d1303069be, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=BMS的PD-1明星单抗Opdivo引领其第二季度销售额达57亿美元, objectType=article, longId=145300, objectId=2ce11453002a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ce11453002a, replyNumber=0, likeNumber=74, createdTime=2018-07-29, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ce11453002a, moduleTitle=BMS的PD-1明星单抗Opdivo引领其第二季度销售额达57亿美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ce11453002a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303068, encodeId=3ba713030684d, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=BMS的Opdivo / Yervoy组合治疗肺癌申请通过, objectType=article, longId=141390, objectId=e14c141390a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e14c141390a6, replyNumber=0, likeNumber=68, createdTime=2018-06-24, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e14c141390a6, moduleTitle=BMS的Opdivo / Yervoy组合治疗肺癌申请通过, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e14c141390a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303067, encodeId=979b130306ef1, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=重磅！国内PD-1肿瘤药Opdivo获批上市开启肺癌免疫肿瘤治疗时代, objectType=article, longId=140903, objectId=fa7c14090392, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa7c14090392, replyNumber=0, likeNumber=58, createdTime=2018-06-17, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa7c14090392, moduleTitle=重磅！国内PD-1肿瘤药Opdivo获批上市开启肺癌免疫肿瘤治疗时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa7c14090392)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303066, encodeId=3f6213030661b, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Opdivo/Yervoy联合免疫疗法获批成为晚期肾癌的一线治疗药物, objectType=article, longId=135804, objectId=accc1358048f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=accc1358048f, replyNumber=0, likeNumber=71, createdTime=2018-04-20, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=accc1358048f, moduleTitle=Opdivo/Yervoy联合免疫疗法获批成为晚期肾癌的一线治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=accc1358048f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303065, encodeId=0ac91303065f3, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=FDA批准了Opdivo每四周一次的剂量, objectType=article, longId=132575, objectId=43221325e59a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43221325e59a, replyNumber=0, likeNumber=56, createdTime=2018-03-17, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43221325e59a, moduleTitle=FDA批准了Opdivo每四周一次的剂量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43221325e59a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303064, encodeId=7d37130306444, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Opdivo / Yervoy联用在肺癌中的PFS上优于单一化疗, objectType=article, longId=129142, objectId=752c12914223, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=752c12914223, replyNumber=0, likeNumber=59, createdTime=2018-02-08, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=752c12914223, moduleTitle=Opdivo / Yervoy联用在肺癌中的PFS上优于单一化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=752c12914223)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303063, encodeId=52ac130306356, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=治疗黑色素瘤 Opdivo®(Nivolumab)疗效优于Yervoy®(Ipilimumab), objectType=article, longId=122648, objectId=9aba12264896, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aba12264896, replyNumber=0, likeNumber=67, createdTime=2017-12-09, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aba12264896, moduleTitle=治疗黑色素瘤 Opdivo®(Nivolumab)疗效优于Yervoy®(Ipilimumab), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9aba12264896)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303062, encodeId=3a8b130306271, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Opdivo®（Nivolumab）用于中国实体瘤患者的安全性和药代动力学研究公布初步结果, objectType=article, longId=122554, objectId=1415122554e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1415122554e2, replyNumber=0, likeNumber=79, createdTime=2017-12-08, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1415122554e2, moduleTitle=Opdivo®（Nivolumab）用于中国实体瘤患者的安全性和药代动力学研究公布初步结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1415122554e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303061, encodeId=6a8e130306156, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=Lirilumab/ Opdivo组合显示“没有明确的证据”, objectType=article, longId=121404, objectId=43a812140405, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43a812140405, replyNumber=0, likeNumber=72, createdTime=2017-11-27, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43a812140405, moduleTitle=Lirilumab/ Opdivo组合显示“没有明确的证据”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43a812140405)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303060, encodeId=2780130306036, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=历史性一刻，BMS单抗Opdivo强势来袭，中国**款提交上市申请的PD-1/PD-L1类药物, objectType=article, longId=118721, objectId=3b83118e218f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b83118e218f, replyNumber=0, likeNumber=0, createdTime=2017-11-05, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b83118e218f, moduleTitle=历史性一刻，BMS单抗Opdivo强势来袭，中国**款提交上市申请的PD-1/PD-L1类药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b83118e218f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303059, encodeId=c9f813030596f, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=AACR 2017：肿瘤免疫治疗全新猛料! Opdivo一线治疗NSCLC或将重获转机（CheckMate 026）, objectType=article, longId=95184, objectId=6b1595184c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b1595184c3, replyNumber=0, likeNumber=82, createdTime=2017-04-10, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b1595184c3, moduleTitle=AACR 2017：肿瘤免疫治疗全新猛料! Opdivo一线治疗NSCLC或将重获转机（CheckMate 026）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b1595184c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303058, encodeId=25f31303058fd, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=百时美施贵宝 Opdivo 治疗转移性结肠直肠癌获得 FDA 优先审查, objectType=article, longId=94937, objectId=aed19493eed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aed19493eed, replyNumber=0, likeNumber=51, createdTime=2017-04-08, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aed19493eed, moduleTitle=百时美施贵宝 Opdivo 治疗转移性结肠直肠癌获得 FDA 优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aed19493eed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303057, encodeId=9189130305e22, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=百时美Opdivo获欧盟CHMP推荐批准，将成欧洲治疗头颈部鳞状细胞癌（SCCHN）的肿瘤免疫疗法, objectType=article, longId=94071, objectId=2032940e105, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2032940e105, replyNumber=0, likeNumber=64, createdTime=2017-03-31, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2032940e105, moduleTitle=百时美Opdivo获欧盟CHMP推荐批准，将成欧洲治疗头颈部鳞状细胞癌（SCCHN）的肿瘤免疫疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2032940e105)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303056, encodeId=8f1d130305642, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=重磅！美国FDA批准百时美PD-1免疫疗法Opdivo治疗晚期尿路上皮癌（mUC）（CheckMate-275）, objectType=article, longId=88389, objectId=549e88389de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=549e88389de, replyNumber=0, likeNumber=66, createdTime=2017-02-08, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=549e88389de, moduleTitle=重磅！美国FDA批准百时美PD-1免疫疗法Opdivo治疗晚期尿路上皮癌（mUC）（CheckMate-275）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=549e88389de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1303055, encodeId=da4c130305595, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, objectTitle=强强联手！百时美与强生合作开发免疫组合疗法Opdivo+Darzalex，治疗多种肿瘤, objectType=article, longId=86946, objectId=6e9a869465e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e9a869465e, replyNumber=0, likeNumber=60, createdTime=2017-01-09, rootId=0, userName=119337457, userId=fda6311, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e9a869465e, moduleTitle=强强联手！百时美与强生合作开发免疫组合疗法Opdivo+Darzalex，治疗多种肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e9a869465e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Opdivo

2020-05-29

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

百时美施贵宝的PD-1单抗Opdivo未来增长前景堪忧

2019-01-27

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

FDA延长了对Opdivo/Yervoy联合治疗方案的审查

2018-10-23

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

澳大利亚TGA批准OPDIVO（nivolumab）治疗肝癌

2018-09-26

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Opdivo vs. Keytruda中国PD-1/L1市场的激烈角逐

2018-08-30

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

美国食品药品监督管理局批准Opdivo®新适应症成为全球近20年来用于经治小细胞肺癌的新药

2018-08-23

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

BMS的PD-1明星单抗Opdivo引领其第二季度销售额达57亿美元

2018-07-29

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

BMS的Opdivo / Yervoy组合治疗肺癌申请通过

2018-06-24

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

重磅！国内PD-1肿瘤药Opdivo获批上市开启肺癌免疫肿瘤治疗时代

2018-06-17

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Opdivo/Yervoy联合免疫疗法获批成为晚期肾癌的一线治疗药物

2018-04-20

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

FDA批准了Opdivo每四周一次的剂量

2018-03-17

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Opdivo / Yervoy联用在肺癌中的PFS上优于单一化疗

2018-02-08

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

治疗黑色素瘤 Opdivo®(Nivolumab)疗效优于Yervoy®(Ipilimumab)

2017-12-09

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Opdivo®（Nivolumab）用于中国实体瘤患者的安全性和药代动力学研究公布初步结果

2017-12-08

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

Lirilumab/ Opdivo组合显示“没有明确的证据”

2017-11-27

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

历史性一刻，BMS单抗Opdivo强势来袭，中国**款提交上市申请的PD-1/PD-L1类药物

2017-11-05

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

AACR 2017：肿瘤免疫治疗全新猛料! Opdivo一线治疗NSCLC或将重获转机（CheckMate 026）

2017-04-10

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

百时美施贵宝 Opdivo 治疗转移性结肠直肠癌获得 FDA 优先审查

2017-04-08

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

百时美Opdivo获欧盟CHMP推荐批准，将成欧洲治疗头颈部鳞状细胞癌（SCCHN）的肿瘤免疫疗法

2017-03-31

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

重磅！美国FDA批准百时美PD-1免疫疗法Opdivo治疗晚期尿路上皮癌（mUC）（CheckMate-275）

2017-02-08

119337457 (审核中...)

前往app查看评论内容

#Opdivo#

强强联手！百时美与强生合作开发免疫组合疗法Opdivo+Darzalex，治疗多种肿瘤

2017-01-09

科室
- - 订阅+
  - 更多科室
工具
服务